source
- US biotech M&A surges as Chinese licensing deals dominate 2026 marketLocust Walk reports that China now accounts for 58% of global licensing deal value in 2026, while the United States share has dropped to 26%. Despite the licensing shift, US biotech companies are…
- Novo reports 25% average weight loss in women using CagriSema, with greatest loss in premenopausal patientsNovo's next-generation GLP-1 drug CagriSema showed substantial weight loss in women enrolled in the Phase 3 REDEFINE 1 trial. Women in the study lost about 25% of their body weight after 68 weeks,…